

Alexander Treiber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3535112/publications.pdf>

Version: 2024-02-01

14
papers

900
citations

840776

11
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

905
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 736-745. | 2.5 | 288 |
| 2 | Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1400-1407. | 3.3 | 284 |
| 3 | Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. <i>Xenobiotica</i> , 2012, 42, 901-910. | 1.1 | 69 |
| 4 | The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 489-503. | 2.5 | 56 |
| 5 | Structure-Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT-62206: a Potent, Brain-Penetrant Dual Orexin ₁ /Orexin ₂ Receptor Antagonist. <i>ChemMedChem</i> , 2014, 9, 2486-2496. | 3.2 | 33 |
| 6 | Macitentan Does Not Interfere with Hepatic Bile Salt Transport. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 130-143. | 2.5 | 33 |
| 7 | N-Glycine-sulfonamides as potent dual orexin 1/orexin 2 receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5729-5733. | 2.2 | 30 |
| 8 | Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1884-1891. | 2.2 | 30 |
| 9 | The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders. <i>ChemMedChem</i> , 2020, 15, 2286-2305. | 3.2 | 28 |
| 10 | Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2016, 55, 369-380. | 3.5 | 23 |
| 11 | Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach. <i>ChemMedChem</i> , 2016, 11, 2132-2146. | 3.2 | 14 |
| 12 | The metabolism of the dual endothelin receptor antagonist macitentan in rat and dog. <i>Xenobiotica</i> , 2016, 46, 253-267. | 1.1 | 6 |
| 13 | From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved <i>in vivo</i> Efficacy in Dogs. <i>ChemMedChem</i> , 2020, 15, 430-448. | 3.2 | 4 |
| 14 | The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross-species comparison of its cytochrome P450 induction pattern. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00619. | 2.4 | 2 |